A multicentre, single arm, open-label, phase IV study to evaluate the immunogenicity and safety of subcutaneously administered r-hIFN beta-1a (Rebif) using clone 484-39 in the treatment of subjects with Relapsing Remitting Multiple Sclerosis

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2004
This article has no abstract
Epistemonikos ID: b300abfb1f0879f7645601626656125277d5ec7e
First added on: Jan 21, 2025